We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Alliance to Develop New DNA Diagnostic Tools

By HospiMedica staff writers
Posted on 22 Mar 2001
A broad five-year alliance in the field of DNA-based diagnostics has been formed by deCode genetics (Reykjavik, Iceland) and Roche Diagnostics (Basel, Switzerland). The alliance builds on decode's unique population genomics resources and bioinformatics expertise and on the global leadership of Roche in the field of molecular diagnostics.

The two companies will use the genomics research and informatics of decode to develop an integrated suite of new diagnostic products and services for diagnosing common diseases and for predicting individual predisposition. The partners will also develop point-of-care informatics products and services that will help doctors evaluate DNA-based test results, in order to optimize the early treatment and prevention of disease.

"By bringing together our research programs and market leadership with deCode's integrated approach to the genetics of common diseases, we hope to create a new paradigm for the use of DNA-based diagnostics in the treatment and prevention of these diseases,” said Heino von Prondzynski, head of Roche Diagnostics.



Related Links:
Roche Diagnostics
deCode genetics

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
New
Automated Urinalysis Solution
UN-9000
New
HPV Molecular Test
BD Onclarity HPV Assay

Latest Industry News

Partnership Aims to Bring Risk-Guided CKD Care to Health Systems
22 Mar 2001  |   Industry

AI-Powered Multi-Functional Analyzer Wins German Innovation Award
22 Mar 2001  |   Industry

Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
22 Mar 2001  |   Industry



ADLM